Shanghai and Hong Kong, China, October 9, 2026
Antengene Corporation Limited has announced that it will present new preclinical results for ATG-207, an investigational αCD3-TGF-β bifunctional fusion protein, at the 2026 American College of Rheumatology (ACR) Annual Meeting. The candidate is being developed for T cell-mediated autoimmune diseases, where persistent immune cell activity can cause inflammation and damage healthy tissues. The presentation is scheduled for November 9, 2026, in Orlando, Florida, as part of the scientific meeting running from November 6 to November 11. ATG-207 is designed to combine T-cell modulation with targeted transforming growth factor-beta (TGF-β) signaling, with the aim of reducing harmful immune responses while promoting regulatory T cells. The latest findings provide further preclinical evidence supporting Antengene’s research into potential therapies that could help restore immune balance in autoimmune conditions. ATG-207 remains an investigational, preclinical-stage candidate, and its potential clinical benefits have not yet been established in human clinical trials.
ATG-207 Combines CD3 Targeting With TGF-β Signaling
ATG-207 has been engineered by combining an anti-CD3 antibody with a peptide-masked, TGFβRIII-biased TGF-β domain. CD3 is a component of the T-cell receptor complex, while TGF-β plays an important role in immune regulation and the differentiation and maintenance of regulatory T cells (Tregs). These cells help control excessive immune activity and maintain tolerance to the body’s own tissues. However, systemic TGF-β activity can affect multiple biological pathways, creating safety challenges when developing therapies based on this signaling mechanism. Antengene designed ATG-207 to favor interactions with TGFβ receptor III (TGFβRIII) while limiting unwanted receptor engagement. In preclinical testing, the candidate demonstrated preferential binding to TGFβRIII, with no detectable binding to TGFβRII in the reported surface plasmon resonance assay. The engineered masking mechanism also reduced binding affinity compared with unmasked TGF-β. This approach is intended to provide more controlled immune modulation, although further research will be necessary to determine whether these design features translate into meaningful safety and efficacy advantages in humans.
Preclinical Studies Show Regulatory T-Cell Induction
The reported research evaluated ATG-207 through laboratory experiments, cell-based assays and animal models of autoimmune disease. The candidate demonstrated attenuated T-cell activation signaling and reduced proinflammatory cytokine production compared with the parental anti-CD3 antibody in the reported assays. It also reduced surface T-cell receptor expression and activated TGF-β pathway signaling more strongly in T cells than in CD3-negative cells. Importantly, ATG-207 induced regulatory T cells in ex vivo experiments using cells obtained from healthy donors and patients with systemic lupus erythematosus (SLE). In animal research, a mouse surrogate of ATG-207 demonstrated therapeutic activity in experimental autoimmune encephalomyelitis, collagen-induced arthritis and adoptive T-cell transfer colitis models. These models represent different forms of immune-mediated disease and provide preliminary evidence for investigating the candidate across multiple indications. The company also reported that ATG-207 and its mouse surrogate were well tolerated in a repeat-dose mouse toxicology study and that the molecule showed favorable stability under several stress conditions. These findings are preclinical results, meaning they cannot establish effectiveness or safety in people, and animal outcomes may not predict clinical performance.
Advertisement
Antengene Prepares to Present Findings at ACR 2026
Antengene will present the research under the title Preclinical Characterization of ATG-207, a Masked and TGFβRIII-Biased αCD3-TGF-β Bi-specific Fusion Protein, for the Treatment of T Cell-Related Autoimmune Diseases. The poster is listed as abstract number 0974 in Poster Session B, focusing on T-cell biology and targets in autoimmune and inflammatory disease. The presentation is scheduled for November 9, 2026, from 10:30 a.m. to 12:30 p.m. Eastern Time. The work reflects Antengene’s broader effort to develop innovative biologic medicines for diseases with significant unmet medical needs. Further development of ATG-207 will depend on additional research to establish its pharmacological properties, safety profile, appropriate dosing and potential suitability for clinical testing. If subsequent studies support its progression, the candidate could contribute to research into new approaches for T cell-mediated autoimmune diseases. For now, the ACR presentation represents an opportunity to communicate its scientific rationale and preclinical findings to the rheumatology and immunology research communities.
Source: Antengene press release
